A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

PURPOSE: To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer. METHODS: Fifty-three patients with advanced cancer received oral sorafenib 400 mg bid in continuous 28-day cycles in this open-label study. Left ventricular ejection...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolcher, Anthony W., Appleman, Leonard J., Shapiro, Geoffrey I., Mita, Alain C., Cihon, Frank, Mazzu, Arthur, Sundaresan, Pavur R.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064895/
https://www.ncbi.nlm.nih.gov/pubmed/20521052
http://dx.doi.org/10.1007/s00280-010-1372-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064895/
https://www.ncbi.nlm.nih.gov/pubmed/20521052
http://dx.doi.org/10.1007/s00280-010-1372-3

Ejemplares similares